$0.31
-0.00 (-0.48%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MREO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 9 with posted results
Held by 6 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MARSHALL WACE, LLP, +1 more) · FINRA short interest 3.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsNCT04761198results2025-03-17Objective Response Rate (ORR) as Assessed Based on Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Etigilimab, Nivolumab | Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor | 76 | 2023-10-30actual | 2025-03-17 |
| A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.NCT03636347Change from baseline on blood biomarkers of neutrophil elastase activity compared to baseline and placeboRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2 | Alpha 1-Antitrypsin Deficiency, Emphysema, COPD | 99 | 2022-03-02actual | 2022-04-14 |
| A 6 Month Safety Extension Study of MBGS205NCT02908074results2023-05-18Percent Change in Bone Mineral Density Measured by DEXA (g/cm^2) From Baseline in Study MBGS205 to Week 48 in Study MBGS206Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BGS649 | Hypogonadotropic Hypogonadism | 143 | 2018-09-08actual | 2023-05-18 |
| The Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsNCT03498170Maximum Measurable Plasma Concentration (Cmax) BCT197 in the presence and absence of itraconazole.Open-label · Treatment | Phase 1 | Completed | Drug: BCT197, Itraconazole 200 mg | Interaction | 16 | 2018-05-03actual | 2018-05-18 |
| Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic HypogonadismNCT02730169results2020-11-25Percentage of Patients With Normalised Testosterone After 24 Weeks of Study TreatmentRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BGS649, Placebo | Hypogonadotropic Hypogonadism | 271 | 2018-02-15actual | 2022-09-14 |
| Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseNCT02700919results2020-11-30Change From Baseline in FEV1 to Day 7 - ITT PopulationRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BCT197, Placebo | Pulmonary Disease, Chronic Obstructive | 282 | 2017-11-08actual | 2020-11-30 |
| The Effect of Azithromycin on BCT197 Exposure in Healthy Male VolunteersNCT02926326Maximum Measurable Plasma Concentration (Cmax) BCT197 in the presence and absence of Azithromycin.Open-label · Treatment | Phase 1 | Completed | Drug: BCT197, Azithromycin | Interaction | 16 | Oct 2016actual | 2016-10-24 |
| Safety & Efficacy of BCT197 in Patients Undergoing Cardiac SurgeryNCT01336959results2018-11-08Renal Function Measured at 48 Hours Post Cardiac Surgery With Cardiopulmonary Bypass Pump.Randomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: BCT197 Part A, Placebo, BCT197 Part B | Acute Kidney Injury | 91 | Nov 2013actual | 2020-11-06 |
| Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationNCT01332097results2023-03-21Change in FEV1 From Baseline to Day 5 or Baseline to Day 10 Measure: FEV1 Change in Forced Expiry Volume in 1 SecondRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: BCT197, Prednisone placebo, BCT197 placebo, Prednisone | Chronic Obstructive Pulmonary Disease | 183 | May 2013actual | 2023-03-21 |
| Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal MenNCT01200862results2020-10-08Percentage of Patients Achieving Normal Testosterone LevelsRandomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: Investigational new drug company code: BGS649, Placebo | Obese Hypogonadotropic Hypogonadism | 29 | Aug 2012actual | 2020-10-08 |
| BGS649 Monotherapy in Moderate to Severe Endometriosis PatientsNCT01190475results2017-12-14Proportion of Patients Who Develop 2 or More Follicles With Diameter 16 mm or LargerRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Active treatment with a high dose of BGS649, Active treatment with a low dose of BGS649, Placebo treatment to blind study | Endometriosis | 6 | Sep 2011actual | 2020-10-27 |
| A Safety & Efficacy Study of BGS649 in Women With Refractory EndometriosisNCT01116440results2020-10-30Mean Change in Baseline to Week 12 in Numeric Rating Scale Pelvic Pain ScoreRandomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: BGS649, Placebo | Pelvic Pain Associated With Refractory Endometriosis | 27 | Jul 2011actual | 2020-11-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19